Holen Sie sich die Stockscreener-App
30.87
0.66%
-0.25
Schlusskurs vom Vortag:
$31.12
Offen:
$30.87
24-Stunden-Volumen:
287.11K
Relative Volume:
0.24
Marktkapitalisierung:
$2.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.78M
KGV:
-14.99
EPS:
-2.0595
Netto-Cashflow:
$-136.42M
1W Leistung:
+6.46%
1M Leistung:
+13.03%
6M Leistung:
+13.49%
1J Leistung:
-19.70%
1-Tages-Spanne:
$30.63
$31.99
1-Wochen-Bereich:
$27.39
$31.99
52-Wochen-Spanne:
$22.30
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
30.88 | 2.75B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | TD Cowen | Buy |
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares - Investing.com
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q2 2026 Earnings Call Transcript - AOL.com
Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo
Mineralys Grants Equity Awards to New Medical Chief - MyChesCo
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Q3 EPS Estimate for Mineralys Therapeutics Raised by Analyst - MarketBeat
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares - Stock Titan
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56 - Moomoo
What is HC Wainwright's Estimate for MLYS FY2030 Earnings? - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $49 - Moomoo
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback - webull.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock - Investing.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock - MarketBeat
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Earnings Miss - MarketBeat
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside - TradingView
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.75, Implies 78% Upside - TradingView
Transcript : Mineralys Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Mineralys Q2 Results: Net Loss Widens To $241.1 Million - scanx.trade
Mineralys Therapeutics Q2 Earnings Call Highlights - MarketBeat
MLYS: Q2 2026 featured robust launch preparations, strategic capital moves, and strong lorundrostat data - TradingView
Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results - MarketBeat
Earnings call transcript: Mineralys Q2 2026 loss widens, shares fall after hours - Investing.com
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing - Stock Traders Daily
Why is Mineralys Therapeutics stock sliding today? - Investing.com
Why is Mineralys Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest - Stock Titan
Mineralys Therapeutics Q2 Loss Widens - marketscreener.com
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mineralys Therapeutics Inc-Aktie (MLYS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Aug 21 '26 |
Sale |
25.98 |
7,437 |
193,189 |
38,400 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):